Loading data for VRDN — first visit, this takes a few seconds.
Viridian Therapeutics Inc... (VRDN)
NasdaqCM: VRDN
· Real-Time Price · USD
24.80
+0.87 (3.64%)
At close: Aug 20, 2026, 8:00 PM
24.55
+0.20%
After-hours: 7:35 PM
Viridian Therapeutics Inc. (VRDN) Stock Price, Analysis & Data
3.64% (1D)
No data available
| Bid | 24.69 |
| Market Cap | 2.78B |
| Revenue (ttm) | 71.13M |
| Net Income (ttm) | -334.03M |
| Beta | 0.94 |
| EPS (ttm) | -3.4 |
| PE Ratio (ttm) | n/a |
| Forward PE | -8.84 |
| P/B (ttm) | 4.98 |
| P/S (ttm) | 39.02 |
| Earnings Date | Nov 5, 2026 |
| Ask | 29.45 |
| Volume | 1,832,785 |
| Avg. Volume (20D) | 2,010,875 |
| Open | 24.50 |
| Previous Close | 23.93 |
| Day's Range | 23.83 - 24.86 |
| 52-Week Range | 13.18 - 34.29 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VRDN
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TS...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 18, 2014
Employees 252
Stock Exchange NasdaqCM
Ticker Symbol VRDN
Financial Performance
In 2025, Viridian Therapeutics's revenue was 70.85M, an increase of 23,359.93% compared to the previous year's 302K. Earnings were -342.6M, an increase of 26.91%.
Financial StatementsEarnings Surprise
Viridian Therapeutics has released their quarterly earnings on Aug 6, 2026:
Viridian Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2